Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Follow-up of CHIKV VLP Vaccine Booster
NCT06007183Phase 3Active, not recruiting
- Sponsor
- Bavarian Nordic
- Start
- Aug 2023
- Primary completion
- Feb 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of CHIKV VLP vaccine in chikungunya virus infection, sponsored by Bavarian Nordic. Started Aug 2023; status: active, not recruiting.
02
Drugs
CHIKV VLP vaccine
03
Conditions
chikungunya virus infection
Beyond the preview
Go deeper on NCT06007183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007183.